Meetings: National Mammography Quality Assurance Advisory Committee,

[Federal Register: August 11, 2000 (Volume 65, Number 156)]

[Notices]

[Page 49246-49247]

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

[DOCID:fr11au00-60]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

National Mammography Quality Assurance Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: National Mammography Quality Assurance Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on September 28, 2000, 9 a.m. to 6 p.m.

Location: Holiday Inn, Walker/Whetstone Rooms, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Charles A. Finder, Center for Devices and Radiological Health (HFZ-240), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301-594-3332, or

[[Page 49247]]

FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12397. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss FDA oversight of the Mammography Quality Standards Act (the MQSA) inspectors and inspections, the MQSA compliance guidance, and FDA's role under the MQSA in evaluating personnel competency. The committee will also receive updates on the status of accreditation and certification of full field digital mammography, use of small field digital mammography receptors for diagnostic examinations, States as certification agencies under the MQSA, and the Inspection Demonstration Project. The MQSA compliance guidance documents, which are in a question-and-answer format, are available to the public on the Internet at http://www.fda.gov/cdrh/ mammography. This guidance is being updated continually in response to questions that FDA receives from the public. Additional information regarding guidance updates may be obtained by calling the Information Line.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by September 1, 2000. Oral presentations from the public will be scheduled between approximately 9:30 a.m. and 10:30 a.m. on September 28, 2000. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before September 1, 2000, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: August 2, 2000. Linda A. Suydam, Senior Associate Commissioner.

[FR Doc. 00-20342Filed8-10-00; 8:45 am]

BILLING CODE 4160-01-F